LXEO — Lexeo Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1907108 ·
Last close
$2.86
Market Cap
$234.24M
52W High
$10.99
52W Low
$2.55
ADV30
2,615,594
Next earnings
2026-11-16

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -40,399,000 -38,300,000 243,916,000 90,219,000 27,225,000
Jun 2026 0 — -28,020,000 -25,867,000 254,898,000 92,834,000 19,837,000
Mar 2026 0 — -22,333,000 -20,196,000 250,356,000 71,768,000 18,859,000
Dec 2025 0 — -23,116,000 -20,919,000 268,688,000 63,000,000 22,019,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-88,367,000
Investing CF
$-24,954,000
Financing CF
$170,675,000
CapEx
$-331,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.15
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-426,197,000
Inventory
—
Receivables
—
ST Investments
$118,869,000
EBIT TTM
$-87,106,000
Pretax Income TTM
$-87,265,000
Interest Exp TTM
$159,000
Analysts
9

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -109,257,000 -99,961,000 268,688,000 22,019,000 246,669,000 -98,561,000
Dec 2024 0 -105,766,000 -98,333,000 146,942,000 30,100,000 116,842,000 -81,151,000
Dec 2023 0 -68,513,000 -66,394,000 139,807,000 26,272,000 113,535,000 -59,496,000
Dec 2022 654,000 -60,509,000 -59,277,000 97,076,000 210,030,000 -112,954,000 -54,560,000

TTM Snapshot

Revenues TTM
$7,976,000
NetIncome TTM
$-87,265,000
OpCashFlow TTM
—
Assets (Latest)
$254,898,000
Forward EPS
$-1.37

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $2.95 · call volume: 56 · put volume: 104

Peers — same industry

TickerNameMarket CapLastDaily %
PROK PROKIDNEY CORP. $229.87M $1.10 —
PLX Protalix BioTherapeutics, Inc. $242.84M $2.88 —
IPSC Century Therapeutics, Inc. $248.79M $1.37 —
CABA Cabaletta Bio, Inc. $220.03M $1.02 —
OCGN Ocugen, Inc. $256.75M $0.76 —

News headlines (Yahoo Finance, 1h cache)

Lexeo Therapeutics Q3 Earnings Call Highlights
2026-11-16 16:15 · Yahoo
Lexeo Therapeutics shares surge 25% on interim data for LX2020 gene therapy
2026-11-16 14:01 · Yahoo
Lexeo Therapeutics Reports LX2020 Gene Therapy Trial Data and Outlines Potential FDA Accelerated Approval Pathway
2026-11-16 13:47 · Yahoo
Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
2026-11-16 12:00 · Yahoo
Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026
2026-11-15 12:00 · Yahoo
Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
2026-11-02 12:00 · Yahoo
Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout
2026-10-25 14:02 · Yahoo
Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
2026-10-24 07:02 · Yahoo
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
2026-10-19 11:00 · Yahoo
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
2026-10-08 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.